



## Challenges in Cancer-Associated Thrombosis

Guest Editor:

### Dr. Remedios Otero-Candelera

1. Medical Surgical Unit of  
Respiratory Diseases, Hospital  
Universitario Virgen del Rocio,  
Seville, Spain  
2. Instituto de Biomedicina de  
Sevilla (IBIS)/CSIC/Universidad  
de Sevilla, CIBERES, Spain

Deadline for manuscript  
submissions:

**closed (31 May 2022)**

### Message from the Guest Editor

Cancer patients are at increased risk of venous thromboembolism (VTE). VTE incidence associated with cancer has increased due to VTE detection in routine-imaging testing for cancer staging. VTE in cancer presents an increased risk of recurrence, bleeding, and mortality. The updated guidelines recommend either apixaban, rivaroxaban, or low molecular weight heparin (LMWH) for thromboprophylaxis in selected high-risk outpatients with cancer without a contraindication to anticoagulation or drug–drug interactions. Guidelines also consider rivaroxaban, edoxaban or LMWH as options for the treatment of VTE in cancer patients. LMWH, edoxaban, and rivaroxaban are preferred for long-term anticoagulation (at least 6 months). It is considered anticoagulation beyond 6 months in select patients with metastatic disease or those receiving chemotherapy, but biomarkers that guide us on the duration of VTE treatment in cancer patients are not yet established.

In this Special Issue, articles about direct oral anticoagulant drugs in cancer patients and about different approaches to select cancer patients for thromboprophylaxis or to decide the suitable anticoagulation duration will be reported.





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI